Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

101. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

102. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

103. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

104. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease Full Text available with Trip Pro

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis.To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients.In this 4-week, double-blind, placebo

2009 EvidenceUpdates Controlled trial quality: predicted high

105. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Full Text available with Trip Pro

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction (...) following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls. After extensive multivariable adjustment, current use of proton pump inhibitors was associated with an increased risk of reinfarction (adjusted odds ratio [OR] 1.27, 95% confidence interval [CI] 1.03-1.57). We found no association with more distant exposure to proton pump inhibitors or in multiple sensitivity analyses. In a stratified analysis, pantoprazole, which does not inhibit

2009 EvidenceUpdates

106. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. (Abstract)

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel.In the PRINCIPLE-TIMI 44 (...) trial, the primary outcome was inhibition of platelet aggregation at 6 h assessed by light-transmission aggregometry. In the TRITON-TIMI 38 trial, the primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. In both studies, PPI use was at physician's discretion. We used a multivariable Cox model with propensity score to assess the association of PPI use with clinical outcomes.In the PRINCIPLE-TIMI 44 trial, 201 patients undergoing elective percutaneous coronary

2009 Lancet

107. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Article Text Aetiology

2009 Evidence-Based Medicine

108. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis

Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C CRD summary The review found a significantly lower rate of clinically important (...) bleeding when using proton pump inhibitors rather than histamine-2 receptor antagonists in the prevention of stress-related mucosal disease in critically ill patients. Rates of nosocomial pneumonia were similar. The reliability of the authors’ conclusions is unclear due to some methodological weaknesses and differences between the small number of studies. Authors' objectives To evaluate the effectiveness of proton pump inhibitors compared to histamine-2 receptor antagonists in the prevention of stress

2009 DARE.

109. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials

The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

110. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials

Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

111. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. (Abstract)

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Substantial physician workload and high costs are associated with the treatment of dyspepsia in primary health care. Despite the availability of consensus statements and guidelines, the most cost-effective empirical strategy for initial management (...) , and proton pump inhibitor (step-up; n=341), or these drugs in the reverse order (step-down; n=323), by use of a computer-generated sequence with blocks of six. Each step lasted 4 weeks and treatment only continued with the next step if symptoms persisted or relapsed within 4 weeks. Primary outcomes were symptom relief and cost-effectiveness of initial management at 6 months. Analysis was by intention to treat (ITT); the ITT population consisted of all patients with data for the primary outcome at 6

2009 Lancet Controlled trial quality: predicted high

112. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

113. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients Full Text available with Trip Pro

Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients Radiofrequency (RF) energy delivery is an endoscopic procedure developed for the treatment of gastro-oesophageal reflux disease.To compare RF and a proton pump inhibitor strategy (PPI) in PPI-dependent patients by carrying out a prospective, randomized trial.Patients with PPI-dependent typical reflux symptoms were randomly allocated to either RF or PPI regimen alone

2008 EvidenceUpdates Controlled trial quality: uncertain

114. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor? (Abstract)

Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor? In patients with proton pump inhibitor (PPI)-resistant symptoms, ambulatory 24-h pH-impedance monitoring can be used to assess whether a relationship exists between symptoms and reflux episodes. Until now, it is unclear whether combined pH-impedance monitoring in these patients should be performed on or off PPI.Thirty patients with symptoms of heartburn, chest pain

2008 EvidenceUpdates Controlled trial quality: uncertain

115. Proton-pump inhibitor use and the risk for community-acquired pneumonia. (Abstract)

Proton-pump inhibitor use and the risk for community-acquired pneumonia. Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP).To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom.Nested case-control study.The General Practice Research Database (1987 to 2002) in the United Kingdom.Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up (...) matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]).Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP.Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.

2008 Annals of Internal Medicine

116. Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Full Text available with Trip Pro

Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) inhibitors improve global symptoms in non-ulcer dyspepsia Article Text Therapeutics Review: prokinetics, histamine H 2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse

2008 Evidence-Based Medicine

117. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding

GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005415. DOI: 10.1002/14651858.CD005415.pub2. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631-40. Barkun AN, Herba K, Adam V, et al. The cost-effectiveness of high-dose proton pump inhibition after endoscopy (...) Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding Al-Sabah S, Barkun A N, Herba K, Adam V, Fallone C, Mayrand S, Pomier-Layrargues G, Kennedy W, Bardou M Record Status This is a critical abstract of an economic evaluation that meets the criteria

2008 NHS Economic Evaluation Database.

118. Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants

Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Gieruszczak-Bialek D, Skorka A, Szajewska H CRD summary The review evaluated the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease in infants (...) and found limited evidence that omeprazole significantly reduced reflux. The review was generally well conducted. The authors’ conclusion that there was insufficient evidence for the use of proton pump inhibitors for treatment of gastro-oesophageal reflux disease in infants seems reliable. Authors' objectives To evaluate the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease (GORD) in infants. Searching MEDLINE (1966-2007), EMBASE (1980-2007

2008 DARE.

119. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). Full Text available with Trip Pro

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). To determine the cost effectiveness of Helicobacter pylori "test and treat" compared with empirical acid suppression in the initial management of patients with dyspepsia in primary care.Randomised controlled trial.80 general practices in the United Kingdom.699 patients aged 18-65 who presented to their general practitioner (...) with epigastric pain, heartburn, or both without "alarm symptoms" for malignancy.H pylori 13C urea breath test plus one week of eradication treatment if positive or proton pump inhibitor alone; subsequent management at general practitioner's discretion.Cost effectiveness in cost per quality adjusted life year (QALY) (EQ-5D) and effect on dyspeptic symptoms at one year measured with short form Leeds dyspepsia questionnaire.343 patients were randomised to testing for H pylori, and 100 were positive

2008 BMJ Controlled trial quality: uncertain

120. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Saini S D, Schoenfeld P, Fendrick A M, Scheiman J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of long-term therapy with low-dose aspirin (ASA) plus proton-pump inhibitor (PPI) co-therapy, compared with ASA alone, for the prevention of upper gastrointestinal bleeding

2008 NHS Economic Evaluation Database.